Taysha Gene Therapies Inc (TSHA)

$2.44 +0.07 (2.95%)
Market Cap 508.75M
Revenue (ttm) 8.33M
Net Income (ttm) -89.30M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -1,072.03%
Debt to Equity Ratio 0.77
Volume 2,156,900
Avg Vol 4,104,944
Day's Range N/A - N/A
Shares Out 214.66M
Stochastic %K 30%
Beta 1.04
Analysts Strong Sell
Price Target $8.35

Company Profile

Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of SLC13A5 deficiency; TSHA-113 for t...

Industry: Biotechnology
Sector: Healthcare
Phone: 214 612 0000
Address:
3000 Pegasus Park Drive, Suite 1430, Dallas, United States
quickaspeter
quickaspeter Jun. 25 at 3:16 PM
$TSHA https://finance.yahoo.com/news/bofa-reiterates-buy-rating-relay-195145078.html
0 · Reply
wwmeinc
wwmeinc Jun. 24 at 3:08 PM
$TSHA $CAPR $SRPT .....Really looking like this 'new' FDA in gene therapies is quite fair/measured....might be early in their mandate but the signs do seem to be....go for it...we want to see these treatments...maybe I am reading too much into their moves...but they do seem to be even-handed in their decisions when warranted....pause on SRPT gene seems prudent to understand what is really going on as deaths are of real concern for all...the science progresses though....just some thoughts. glta https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-will-not-convene-expert-panel-capricor-therapeutics-dmd-cell-therapy-2025-06-24/
0 · Reply
M_007_
M_007_ Jun. 20 at 2:07 PM
$TSHA
0 · Reply
strategicmind
strategicmind Jun. 17 at 4:08 PM
$TSHA Great news out of the FDA today!! With more to come https://x.com/drmakaryfda/status/1934990634479133148?s=46
1 · Reply
KingSwan4226
KingSwan4226 Jun. 16 at 3:57 PM
$VXRT Potential here is huge -thats why this group of well read intelligent longs is in for the long haul - thanks guys for all the info over the years ✨$SLS $ALT $TSHA might want to check it out 😉
2 · Reply
wwmeinc
wwmeinc Jun. 15 at 7:21 PM
$TSHA ...Just reading the $SRPT disaster unfolding...not good to see at all....safety is and always will be key in biotech...trial being paused....press conf. June 16/25...Monday 8:00am ET....glta https://www.marketwatch.com/press-release/sarepta-provides-safety-update-for-elevidys-and-initiates-steps-to-strengthen-safety-in-non-ambulatory-individuals-with-duchenne-2b48610d?mod=mw_quote_news_seemore
0 · Reply
Dark_Horse_Investments
Dark_Horse_Investments Jun. 13 at 7:47 PM
$TSHA thanks to Israel, not a good day. We wont see $3 for a looong while... let the story unfold, patience.
0 · Reply
Nikolaos01
Nikolaos01 Jun. 13 at 7:08 PM
$TSHA
0 · Reply
KING_OF_BIO
KING_OF_BIO Jun. 13 at 6:36 PM
$TSHA My favorite stock in the world :) Keep buying - selling now is for quitters
0 · Reply
wwmeinc
wwmeinc Jun. 13 at 2:12 PM
$TSHA ....Some news from the other side of the globe...strengthening the Japanese drug R & D biotech sector....good move really...right in their backyard...plus probably gives them some 'first dibs' on any discoveries...or so I think...just some thoughts...glta https://www.fiercebiotech.com/biotech/astellas-offers-lab-space-start-ups-help-japanese-biotechs-go-global
0 · Reply
Latest News on TSHA
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Jun 6, 2025, 8:00 AM EDT - 19 days ago

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Taysha Gene Therapies Announces Details for Oral Presentations at the 2025 IRSF Rett Syndrome Scientific Meeting Reviewing Recent Updates from the TSHA-102 Clinical Program

Jun 3, 2025, 5:17 PM EDT - 22 days ago

Taysha Gene Therapies Announces Details for Oral Presentations at the 2025 IRSF Rett Syndrome Scientific Meeting Reviewing Recent Updates from the TSHA-102 Clinical Program

Why Is Taysha Gene Therapies Stock Trading Higher On Thursday?

May 29, 2025, 1:06 PM EDT - 27 days ago

Why Is Taysha Gene Therapies Stock Trading Higher On Thursday?

Taysha Gene Therapies Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants

May 28, 2025, 10:40 PM EDT - 27 days ago

Taysha Gene Therapies Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants

Taysha Gene Therapies Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

May 28, 2025, 4:02 PM EDT - 4 weeks ago

Taysha Gene Therapies Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Taysha Gene Therapies Announces Pivotal Part B Trial Design Details for TSHA-102 in Rett Syndrome Enabled by IRSF Natural History Data and Positive Clinical Data from Part A of the REVEAL Adult/Adolescent and Pediatric Trials Evaluating TSHA-102

May 28, 2025, 4:01 PM EDT - 4 weeks ago

Taysha Gene Therapies Announces Pivotal Part B Trial Design Details for TSHA-102 in Rett Syndrome Enabled by IRSF Natural History Data and Positive Clinical Data from Part A of the REVEAL Adult/Adolescent and Pediatric Trials Evaluating TSHA-102

Taysha Gene Therapies, Inc. (TSHA) Q1 2025 Earnings Call Transcript

May 15, 2025, 2:07 PM EDT - 5 weeks ago

Taysha Gene Therapies, Inc. (TSHA) Q1 2025 Earnings Call Transcript

Taysha Gene Therapies Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 15, 2025, 8:00 AM EDT - 5 weeks ago

Taysha Gene Therapies Reports First Quarter 2025 Financial Results and Provides Corporate Update

Taysha Gene Therapies to Release First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 15

May 8, 2025, 4:05 PM EDT - 6 weeks ago

Taysha Gene Therapies to Release First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 15

Drug stocks sink as FDA's top vaccine official is ousted in Trump overhaul

Mar 31, 2025, 2:25 PM EDT - 3 months ago

Drug stocks sink as FDA's top vaccine official is ousted in Trump overhaul

BNTX NVAX SLDB SRPT XBI

Taysha Gene Therapies, Inc. (TSHA) Q4 2024 Earnings Call Transcript

Feb 26, 2025, 2:54 PM EST - 4 months ago

Taysha Gene Therapies, Inc. (TSHA) Q4 2024 Earnings Call Transcript

Taysha Gene Therapies Reports Full-Year 2024 Financial Results and Provides Corporate Update

Feb 26, 2025, 8:00 AM EST - 4 months ago

Taysha Gene Therapies Reports Full-Year 2024 Financial Results and Provides Corporate Update

Taysha Gene Therapies to Release Full-Year 2024 Financial Results and Host Conference Call and Webcast on February 26

Feb 19, 2025, 8:00 AM EST - 4 months ago

Taysha Gene Therapies to Release Full-Year 2024 Financial Results and Host Conference Call and Webcast on February 26

Taysha Gene Therapies Is Showing Promise For Rett Syndrome

Jan 27, 2025, 7:53 PM EST - 5 months ago

Taysha Gene Therapies Is Showing Promise For Rett Syndrome

Advance Auto Parts Posts Weak Results, Joins Harrow, Taysha Gene Therapies And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

Nov 14, 2024, 8:25 AM EST - 7 months ago

Advance Auto Parts Posts Weak Results, Joins Harrow, Taysha Gene Therapies And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

AAP

Taysha Gene Therapies, Inc. (TSHA) Q3 2024 Earnings Call Transcript

Nov 13, 2024, 10:48 PM EST - 7 months ago

Taysha Gene Therapies, Inc. (TSHA) Q3 2024 Earnings Call Transcript

Taysha Gene Therapies Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Nov 13, 2024, 4:01 PM EST - 8 months ago

Taysha Gene Therapies Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Taysha Gene Therapies to Present Biodistribution Data from an Analysis Evaluating AAV9 Gene Therapy Delivery at the Upcoming 31st Annual ESGCT Congress

Oct 22, 2024, 8:00 AM EDT - 8 months ago

Taysha Gene Therapies to Present Biodistribution Data from an Analysis Evaluating AAV9 Gene Therapy Delivery at the Upcoming 31st Annual ESGCT Congress

Taysha Gene Therapies: Unjustified Sell-Off - Enough Cash Runway And Promising Rett Syndrome Data

Oct 14, 2024, 12:55 AM EDT - 9 months ago

Taysha Gene Therapies: Unjustified Sell-Off - Enough Cash Runway And Promising Rett Syndrome Data

Taysha Gene Therapies, Inc. (TSHA) Q2 2024 Earnings Call Transcript

Aug 12, 2024, 12:08 PM EDT - 11 months ago

Taysha Gene Therapies, Inc. (TSHA) Q2 2024 Earnings Call Transcript

Taysha Gene Therapies Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Aug 12, 2024, 8:01 AM EDT - 11 months ago

Taysha Gene Therapies Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Worthington Enterprises Posts Downbeat Results, Joins Taysha Gene Therapies, General Mills And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

Jun 26, 2024, 7:36 AM EDT - 1 year ago

Worthington Enterprises Posts Downbeat Results, Joins Taysha Gene Therapies, General Mills And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

GIS

What's Going On With Taysha Gene Therapies Stock Tuesday?

Jun 18, 2024, 11:42 AM EDT - 1 year ago

What's Going On With Taysha Gene Therapies Stock Tuesday?

Taysha Gene Therapies Announces Positive Clinical Data Across Adult and Pediatric Patients from Low Dose Cohort in Ongoing REVEAL Phase 1/2 Trials Evaluating TSHA-102 in Rett Syndrome

Jun 18, 2024, 7:30 AM EDT - 1 year ago

Taysha Gene Therapies Announces Positive Clinical Data Across Adult and Pediatric Patients from Low Dose Cohort in Ongoing REVEAL Phase 1/2 Trials Evaluating TSHA-102 in Rett Syndrome

Taysha Gene Therapies to Present Clinical Data from Both REVEAL Phase 1/2 Trials During Company-Hosted Webcast and at 2024 IRSF Rett Syndrome Scientific Meeting

Jun 12, 2024, 7:00 AM EDT - 1 year ago

Taysha Gene Therapies to Present Clinical Data from Both REVEAL Phase 1/2 Trials During Company-Hosted Webcast and at 2024 IRSF Rett Syndrome Scientific Meeting

Taysha Gene Therapies, Inc. (TSHA) Q1 2024 Earnings Call Transcript

May 15, 2024, 4:55 AM EDT - 1 year ago

Taysha Gene Therapies, Inc. (TSHA) Q1 2024 Earnings Call Transcript

Taysha Gene Therapies Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 14, 2024, 4:01 PM EDT - 1 year ago

Taysha Gene Therapies Reports First Quarter 2024 Financial Results and Provides Corporate Update

Taysha Gene Therapies to Release First Quarter 2024 Financial Results and Host Conference Call and Webcast on May 14

May 7, 2024, 4:05 PM EDT - 1 year ago

Taysha Gene Therapies to Release First Quarter 2024 Financial Results and Host Conference Call and Webcast on May 14

Taysha Gene Therapies Announces Regenerative Medicine Advanced Therapy (RMAT) Designation Granted by U.S. FDA for TSHA-102 in Rett Syndrome

May 2, 2024, 8:00 AM EDT - 1 year ago

Taysha Gene Therapies Announces Regenerative Medicine Advanced Therapy (RMAT) Designation Granted by U.S. FDA for TSHA-102 in Rett Syndrome

Taysha: Initial Rett Syndrome Data Leads To Other 2024 Catalysts

Mar 20, 2024, 12:30 PM EDT - 1 year ago

Taysha: Initial Rett Syndrome Data Leads To Other 2024 Catalysts

Taysha Gene Therapies, Inc. (TSHA) Q4 2023 Earnings Call Transcript

Mar 19, 2024, 9:04 PM EDT - 1 year ago

Taysha Gene Therapies, Inc. (TSHA) Q4 2023 Earnings Call Transcript

Taysha Gene Therapies Reports Full Year 2023 Financial Results and Provides Corporate and Clinical Updates

Mar 19, 2024, 4:01 PM EDT - 1 year ago

Taysha Gene Therapies Reports Full Year 2023 Financial Results and Provides Corporate and Clinical Updates

Taysha Gene Therapies to Release Full-Year 2023 Financial Results, Provide Corporate and Clinical Updates and Host Conference Call on March 19

Mar 14, 2024, 4:26 PM EDT - 1 year ago

Taysha Gene Therapies to Release Full-Year 2023 Financial Results, Provide Corporate and Clinical Updates and Host Conference Call on March 19

Taysha Gene Therapies Announces Updates to TSHA-102 Clinical Program in Rett Syndrome

Feb 29, 2024, 8:00 AM EST - 1 year ago

Taysha Gene Therapies Announces Updates to TSHA-102 Clinical Program in Rett Syndrome

Taysha Gene Therapies Provides Update on Deprioritized Pipeline Programs

Feb 15, 2024, 4:01 PM EST - 1 year ago

Taysha Gene Therapies Provides Update on Deprioritized Pipeline Programs

Taysha Gene Therapies Announces Poster Presentation on TSHA-102 in Rett Syndrome at Upcoming British Paediatric Neurology Association 2024 Annual Conference

Jan 22, 2024, 8:00 AM EST - 1 year ago

Taysha Gene Therapies Announces Poster Presentation on TSHA-102 in Rett Syndrome at Upcoming British Paediatric Neurology Association 2024 Annual Conference

Taysha Gene Therapies Announces First Pediatric Patient Dosed with TSHA-102 in REVEAL Phase 1/2 Pediatric Trial in Rett Syndrome

Jan 10, 2024, 8:00 AM EST - 1 year ago

Taysha Gene Therapies Announces First Pediatric Patient Dosed with TSHA-102 in REVEAL Phase 1/2 Pediatric Trial in Rett Syndrome

Trinity Capital Inc. Provides $40 Million Term Loan to Taysha Gene Therapies

Dec 19, 2023, 7:30 AM EST - 1 year ago

Trinity Capital Inc. Provides $40 Million Term Loan to Taysha Gene Therapies

TRIN

Taysha Gene Therapies Announces Expanded Eligibility in REVEAL Phase 1/2 Adult Trial to Include Adolescent Rett Syndrome Patients

Nov 29, 2023, 8:00 AM EST - 1 year ago

Taysha Gene Therapies Announces Expanded Eligibility in REVEAL Phase 1/2 Adult Trial to Include Adolescent Rett Syndrome Patients

Taysha Gene Therapies, Inc. (TSHA) Q3 2023 Earnings Call Transcript

Nov 14, 2023, 9:53 PM EST - 1 year ago

Taysha Gene Therapies, Inc. (TSHA) Q3 2023 Earnings Call Transcript

Taysha Gene Therapies Reports Third Quarter 2023 Financial Results and Provides Corporate and Clinical Updates

Nov 14, 2023, 4:08 PM EST - 1 year ago

Taysha Gene Therapies Reports Third Quarter 2023 Financial Results and Provides Corporate and Clinical Updates

Taysha Gene Therapies to Release Third Quarter 2023 Financial Results and Host Conference Call and Webcast on November 14

Nov 7, 2023, 8:00 AM EST - 1 year ago

Taysha Gene Therapies to Release Third Quarter 2023 Financial Results and Host Conference Call and Webcast on November 14

Taysha Gene Therapies: TSHA-102's Potential Is A 'Buy'

Nov 3, 2023, 7:41 PM EDT - 1 year ago

Taysha Gene Therapies: TSHA-102's Potential Is A 'Buy'

Taysha Gene Therapies Presents New Preclinical In-vitro Data on TSHA-102 in Rett Syndrome Supporting miRARE Regulation of MECP2 Expression at the European Society of Gene & Cell Therapy (ESGCT) 30th Annual Congress

Oct 24, 2023, 8:00 AM EDT - 1 year ago

Taysha Gene Therapies Presents New Preclinical In-vitro Data on TSHA-102 in Rett Syndrome Supporting miRARE Regulation of MECP2 Expression at the European Society of Gene & Cell Therapy (ESGCT) 30th Annual Congress

Taysha Gene Therapies Announces Two Poster Presentations on TSHA-102 in Rett Syndrome at Upcoming European Society of Gene & Cell Therapy (ESGCT) 30th Annual Congress

Oct 10, 2023, 8:00 AM EDT - 1 year ago

Taysha Gene Therapies Announces Two Poster Presentations on TSHA-102 in Rett Syndrome at Upcoming European Society of Gene & Cell Therapy (ESGCT) 30th Annual Congress

Taysha Gene Therapies Announces Second Patient Dosed with TSHA-102 in the REVEAL Phase 1/2 Adult Trial for the Treatment of Rett Syndrome

Sep 26, 2023, 8:00 AM EDT - 1 year ago

Taysha Gene Therapies Announces Second Patient Dosed with TSHA-102 in the REVEAL Phase 1/2 Adult Trial for the Treatment of Rett Syndrome

Taysha Gene Therapies Provides Update on TSHA-120 Program in Giant Axonal Neuropathy (GAN)

Sep 19, 2023, 4:01 PM EDT - 1 year ago

Taysha Gene Therapies Provides Update on TSHA-120 Program in Giant Axonal Neuropathy (GAN)

Taysha Gene Therapies Announces Fast Track Designation Granted by U.S. FDA for TSHA-102 in Rett Syndrome

Aug 24, 2023, 8:00 AM EDT - 1 year ago

Taysha Gene Therapies Announces Fast Track Designation Granted by U.S. FDA for TSHA-102 in Rett Syndrome

GordonMD® Invests in Private Placement for Taysha Gene Therapies

Aug 21, 2023, 11:28 AM EDT - 2 years ago

GordonMD® Invests in Private Placement for Taysha Gene Therapies

quickaspeter
quickaspeter Jun. 25 at 3:16 PM
$TSHA https://finance.yahoo.com/news/bofa-reiterates-buy-rating-relay-195145078.html
0 · Reply
wwmeinc
wwmeinc Jun. 24 at 3:08 PM
$TSHA $CAPR $SRPT .....Really looking like this 'new' FDA in gene therapies is quite fair/measured....might be early in their mandate but the signs do seem to be....go for it...we want to see these treatments...maybe I am reading too much into their moves...but they do seem to be even-handed in their decisions when warranted....pause on SRPT gene seems prudent to understand what is really going on as deaths are of real concern for all...the science progresses though....just some thoughts. glta https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-will-not-convene-expert-panel-capricor-therapeutics-dmd-cell-therapy-2025-06-24/
0 · Reply
M_007_
M_007_ Jun. 20 at 2:07 PM
$TSHA
0 · Reply
strategicmind
strategicmind Jun. 17 at 4:08 PM
$TSHA Great news out of the FDA today!! With more to come https://x.com/drmakaryfda/status/1934990634479133148?s=46
1 · Reply
KingSwan4226
KingSwan4226 Jun. 16 at 3:57 PM
$VXRT Potential here is huge -thats why this group of well read intelligent longs is in for the long haul - thanks guys for all the info over the years ✨$SLS $ALT $TSHA might want to check it out 😉
2 · Reply
wwmeinc
wwmeinc Jun. 15 at 7:21 PM
$TSHA ...Just reading the $SRPT disaster unfolding...not good to see at all....safety is and always will be key in biotech...trial being paused....press conf. June 16/25...Monday 8:00am ET....glta https://www.marketwatch.com/press-release/sarepta-provides-safety-update-for-elevidys-and-initiates-steps-to-strengthen-safety-in-non-ambulatory-individuals-with-duchenne-2b48610d?mod=mw_quote_news_seemore
0 · Reply
Dark_Horse_Investments
Dark_Horse_Investments Jun. 13 at 7:47 PM
$TSHA thanks to Israel, not a good day. We wont see $3 for a looong while... let the story unfold, patience.
0 · Reply
Nikolaos01
Nikolaos01 Jun. 13 at 7:08 PM
$TSHA
0 · Reply
KING_OF_BIO
KING_OF_BIO Jun. 13 at 6:36 PM
$TSHA My favorite stock in the world :) Keep buying - selling now is for quitters
0 · Reply
wwmeinc
wwmeinc Jun. 13 at 2:12 PM
$TSHA ....Some news from the other side of the globe...strengthening the Japanese drug R & D biotech sector....good move really...right in their backyard...plus probably gives them some 'first dibs' on any discoveries...or so I think...just some thoughts...glta https://www.fiercebiotech.com/biotech/astellas-offers-lab-space-start-ups-help-japanese-biotechs-go-global
0 · Reply
Midlevelstrader
Midlevelstrader Jun. 12 at 6:22 PM
$TSHA
0 · Reply
wwmeinc
wwmeinc Jun. 12 at 3:00 PM
$TSHA .....No safety issues....nothing to cause concern at all...high dose is working great...an FDA set-up that(insert personal opinion here....)lots of cash on hand now...one Point72 Asset mgmt on-board(Steven Cohen hedge fund)...by the looks of thing Sean has re-built the firm into a nice T/O pkg....but of course.....staying grounded as a biotech investor...but....this little poster presentation is spot on! Thanks. glta
1 · Reply
Eagley3k
Eagley3k Jun. 12 at 2:33 PM
$TSHA most muted reaction to good news I've ever seen!
2 · Reply
quickaspeter
quickaspeter Jun. 12 at 11:52 AM
$TSHA PT raised to $13…💥🚀💰 https://www.gurufocus.com/news/2921535/taysha-gene-therapies-tsha-price-target-raised-amid-high-trial-success-confidence-tsha-stock-news
1 · Reply
quickaspeter
quickaspeter Jun. 12 at 11:13 AM
$TSHA Let’s go!!!
0 · Reply
Eagley3k
Eagley3k Jun. 11 at 11:17 PM
$TSHA
0 · Reply
Dark_Horse_Investments
Dark_Horse_Investments Jun. 11 at 10:59 PM
$TSHA fresh from their website ( may have missed this earlier ) https://ir.tayshagtx.com/static-files/13d0b9a1-1b34-42d8-9231-79c861547884 https://ir.tayshagtx.com/static-files/5eca9801-f524-4289-aca7-9d9a168007e3 digesting the information...
1 · Reply
strategicmind
strategicmind Jun. 11 at 10:34 PM
$TSHA can’t believe no press release yet??
1 · Reply
wwmeinc
wwmeinc Jun. 11 at 7:55 PM
$BB .. $IOVA $TSHA ....Well Ken....have to share...so very true in this mkt! Thanks ;) glta
0 · Reply
Dark_Horse_Investments
Dark_Horse_Investments Jun. 11 at 7:31 PM
$TSHA does anyone have any visuals / slide deck access of the results presented today at IRSF ? There is nothing posted. Would expect a 8-k sec submission of full detail trial results. This is what triggers the Astellas buyout clock. THX in advance.
0 · Reply
Dark_Horse_Investments
Dark_Horse_Investments Jun. 11 at 6:34 PM
$TSHA as always, it opens the morning up and trades down as the day wanes...
1 · Reply
wwmeinc
wwmeinc Jun. 11 at 3:02 PM
$TSHA ...70% success on tap!!....Better than any lottery ticket...nice write-up...;) Thanks. glta TheFly Jun 11, 2025, 11:25 AM Cantor Fitzgerald analyst Kristen Kluska raised the firm’s price target on Taysha Gene Therapies (TSHA) to $13 from $7 and keeps an Overweight rating on the shares. After having attended the IRSF Rett Syndrome Scientific Meeting and spent additional time with Taysha management, the firm has “very high conviction” that the TSHA-102 pivotal trial will succeed, the analyst tells investors. Following data and regulatory path updates, the firm is increasing its view of the odds of success for TSHA-102 to 70% from 35%, the analyst noted.
2 · Reply